WO1999003844A1 - Derives de pyrazine, leur preparation et les medicaments les contenant - Google Patents
Derives de pyrazine, leur preparation et les medicaments les contenant Download PDFInfo
- Publication number
- WO1999003844A1 WO1999003844A1 PCT/FR1998/001542 FR9801542W WO9903844A1 WO 1999003844 A1 WO1999003844 A1 WO 1999003844A1 FR 9801542 W FR9801542 W FR 9801542W WO 9903844 A1 WO9903844 A1 WO 9903844A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- bis
- pyridine
- pyrazine
- hydroxymethyl
- Prior art date
Links
- 0 CC*C1=C(C)*C(C)=C(*)*1 Chemical compound CC*C1=C(C)*C(C)=C(*)*1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to medicaments containing as active ingredient a compound of formula:
- R represents a nitrogen atom
- Ri represents a radical -CO-NR5R6.
- -CO-N CH (CH 2 OH) 2) 2
- -CO-N CH 2 OH
- -CO-N CH 2 -CH (CH 2 OH) 2
- -CO-N CH 2 -CH (CH 2 OH) 2
- R represents a CH residue
- Ri and R 4 are identical and each represents a radical -CO-NR 5 R 6 , -CO-N (CH (CH 2 OH) 2) 2 , -CO-N (CH 2 OH) 2) -CO-N (CH2-CH (CH 2 OH) 2) 2, -CO-N (CH 2 - (CHOH) ⁇ -CH 2 OH) 2 in which n is 0, 1, 2, 3 or 4, -CH 2 -0-R 6 , -NR 5 -CO-R 6 , -CH 2 -NR 5 R 6 , -CH 2 -N (CH 2 OH) 2, -CH 2 -N (CH 2 - (CHOH) y -CH 2 OH) 2 in which y is 0, 1, 2, 3 or 4, -CH 2 -N (CH (CH 2 OH) 2) 2 or -CH 2 -N (CH 2 -CH (CH 2 OH) 2) 2 and R 2 and R 3 each represent a hydrogen atom, either R represents
- R represents a CH residue
- R 2 and R 3 are identical and each represents a radical -CO-NR 5 R 6 , -CO-N (CH (CH 2 OH) 2 ) 2 , -CO-N (CH 2 OH ) 2 , -CO-N (CH 2 -CH (CH 2 OH) 2 ) 2> -CO-N (CH 2 - (CHOH) n -CH 2 OH) 2 in which n is 0, 1, 2 , 3 or 4, -CH 2 -0-R 6 , -NR 5 -CO-R 6 , -CH 2 -NR 5 R6, -CH 2 -N (CH 2 OH) 2, -CH 2 -N (CH 2 - (CHOH) y -CH 2 OH) 2 in which y is 0, 1, 2, 3 or 4, -CH 2 -N (CH (CH 2 OH) 2 ) 2 or -CH 2 -N ( CH 2 -CH (CH 2 OH) 2 ) 2 and R,
- R 5 represents a hydrogen atom or an alkyl radical
- R 6 represents a radical -CH 2 - (CHOH) m-CH 2 OH in which m is equal to 0, 1, 2, 3 or 4, -alk-0-alk-CH 2 OH, -alk-O-alk , -CH (CH 2 OH) 2 , -C (CH 2 OH) 3 , -C (CH 3 ) (CH 2 OH) 2 , -CH 2 -CH (CH 2 OH) 2 or -CH (CH 2 OH ) - (CHOH) x -CH 2 OH in which x is 1, 2, 3 or 4,
- alk represents an alkyl radical
- alkyl radicals contain 1 to 6 carbon atoms in a straight or branched chain.
- the compounds of formula (I) having asymmetric carbon atoms have stereoisomeric forms. These stereoisomers are part of the invention.
- Preferred drugs are those containing a compound of formula
- Particularly preferred drugs are those which contain a compound of formula (I) in which
- R represents a nitrogen atom
- Ri represents a radical -CO-NR5R6, -CO-N (CH 2 - (CHOH) n -CH 2 OH) 2 in which n is equal to 0, 1, 2, 3 or 4, -CH2-NR5R6, -CH 2 -N (CH2- (CHOH) y -CH 2 OH) 2 in which y is 0, 1, 2, 3 or 4, and one of the substituents R 3 or R 4 represents a hydrogen atom and the other is identical to R 1f
- R 2 represents a hydrogen atom
- R 5 represents a hydrogen atom or a radical alkyl
- R 6 represents a radical -CH 2 - (CHOH) m-CH 2 OH in which m is equal to 0, 1, 2, 3 or 4, -alk-0-alk-CH 2 OH, -alk-O -alk, -CH (CH 2 OH) 2 , -C (CH 2 OH) 3 or,
- R represents a CH residue
- Ri and R 4 are identical and each represents a radical -CO-NR 5 R 6
- R 2 and R 3 each represent a hydrogen atom
- R 5 represents a hydrogen atom or a radical alkyl
- R ⁇ represents a radical -CH (CH 2 OH) 2
- R represents a CH residue
- Ri and R 3 are identical and each represent a radical -NR 5 -CO-R 6)
- R 2 and R each represent a hydrogen atom
- R 5 represents a hydrogen atom or a radical alkyl
- R ⁇ represents an -alk-O-alk radical
- R represents a CH residue
- R 2 and R 3 are identical and each represents a radical -CO-NR 5 R 6 , -CH 2 -0-R 6 , -NR 5 -CO-R 6 , -CH 2 -NR 5 R 6 , Ri and R each represent a hydrogen atom
- R 5 represents a hydrogen atom or an alkyl radical
- R 6 represents a radical -alk-O-alk, -CH (CH 2 OH) 2 , - C (CH 2 OH) 3 , -C (CH 3 ) (CH 2 OH) 2 ,
- alk represents an alkyl radical
- medicaments which contain, as active principle, a compound of formula (I) chosen from the following compounds:
- R represents a nitrogen atom
- Ri represents a radical -CO-NRsR ⁇ , -CO-N (CH 2 - (CHOH) n -CH 2 OH) 2 in which n is equal to 0, 1, 2, 3 or 4, -CH 2 -NR 5 R6, -CH 2 -N (CH 2 - (CHOH) y -CH 2 OH) 2 in which y is 0, 1, 2, 3 or 4, and one of substituents R 3 or R represents a hydrogen atom and the other is identical to Ri
- R 2 represents a hydrogen atom
- R5 represents a hydrogen atom or an alkyl radical
- R 6 represents a radical -CH 2 - (CHOH) m-CH 2 OH in which m is 0, 1, 2, 3 or 4, -alk-0-alk-CH 2 OH, -alk-O-alk, -CH (CH 2 OH) 2 , -C (CH 2 OH) 3 or,
- R represents a CH residue
- Ri and R 4 are identical and each represent a radical -CO-NR5R6,
- R2 and R 3 each represent a hydrogen atom
- R 5 represents a hydrogen atom or an alkyl radical
- R ⁇ represents a radical -CH (CH 2 OH) 2 ,
- R represents a CH residue
- Ri and R 3 are identical and each represents a radical -NR 5 -CO-R 6
- R 2 and R 4 each represent a hydrogen atom
- R 5 represents a hydrogen atom or a alkyl radical
- R 6 represents an -alk-O-alk radical
- R represents a CH residue
- R 2 and R 3 are identical and each represents a radical -CO-NR 5 R 6 , -CH 2 -0-R6, -NR 5 -CO-R 6 , -CH 2 -NR 5 R6, Ri and R 4 each represent a hydrogen atom
- R 5 represents an atom of hydrogen or an alkyl radical
- R 6 represents a radical -alk-O-alk, -CH (CH 2 OH) 2 , -C (CH 2 OH) 3 , -C (CH 3 ) (CH 2 OH) 2 ,
- alk represents an alkyl radical
- Ri represents a radical -CO-NR 5 R 6 , -CO-N (CH (CH 2 OH) 2 ) 2 , -CO-N (CH 2 OH) 2 , -CO-N (CH 2 -CH (CH 2 OH) 2 ) 2 , -CO-N (CH 2 - (CHOH) n -CH 2 OH) 2 , and one of the substituents R 3 and R 4 represents a hydrogen atom and the other is identical to Ri and R 2 represents a hydrogen atom can be prepared by the action of a derivative of formula:
- Rc represents a hydrogen atom or an alkyl radical
- Rd represents a radical -CH 2 - (CHOH) m-CH 2 OH in which m is equal to 0, 1, 2, 3 or 4, -alk-0-alk-CH 2 OH, -alk- O-alk, -CH (CH 2 OH) 2 , -C (CH 2 OH) 3 , -C (CH 3 ) (CH 2 OH) 2 -CH 2 -CH (CH 2 OH) 2 or -CH (CH 2 OH) ( CHOH) x -CH 2 OH in which x is equal to 1, 2, 3 or 4 and alk represents an alkyl radical, or Rc and Rd are identical and each represents a radical -CH 2 - (CHOH) n -CH 2
- the operation is carried out in the presence of a condensing agent used in peptide chemistry such as a carbodiimide (for example N, N'-dicyclohexylcarbodiimide) or N.N'- diimidazole carbonyl, in an inert solvent such as an ether (tetrahydrofuran, dioxane for example), an amide (dimethylformamide) or a chlorinated solvent (methylene chloride, 1,2-dichloro-ethane, chloroform for example) at a temperature included between 0 ° C and the reflux temperature of the reaction mixture.
- a condensing agent used in peptide chemistry such as a carbodiimide (for example N, N'-dicyclohexylcarbodiimide) or N.N'- diimidazole carbonyl
- an inert solvent such as an ether (tetrahydrofuran, dioxane for example), an amide (dimethylformamide
- a diester When a diester is used, it is then carried out either in an organic medium, optionally in the presence of an acid acceptor such as an organic nitrogenous base (trialkylamine, pyridine, diaza-1,8-bicyclo [5.4. 0] undecene-7 or diaza-1, 5-bicyclo [4.3.0] nonene-5 for example), in a solvent as mentioned above, or a mixture of these solvents, at a temperature between 0 ° C.
- an acid acceptor such as an organic nitrogenous base (trialkylamine, pyridine, diaza-1,8-bicyclo [5.4. 0] undecene-7 or diaza-1, 5-bicyclo [4.3.0] nonene-5 for example)
- reaction mixture either in a two-phase hydroorganic medium in the presence of an alkaline or alkaline earth base (sodium hydroxide, potassium hydroxide) or of an alkali or alkaline earth metal carbonate or bicarbonate at a temperature comprised between 0 and 40 ° C.
- an alkaline or alkaline earth base sodium hydroxide, potassium hydroxide
- an alkali or alkaline earth metal carbonate or bicarbonate at a temperature comprised between 0 and 40 ° C.
- the derivatives of formula (II) and their reactive derivatives are commercially available or can be obtained by application or adaptation of the methods described by WJ Schut, HIX Mager and W. Berends, Rec. Trav. Chim. Netherlands, 80, 391 (1961) and HIX Mager and W. Berends, Rec. Trav. Chim. Netherlands, 77.827 (1958) or by oxidation of the corresponding dimethyl derivative, for example by means of selenium oxide, in a water-pyridine mixture, at a temperature between 60 and 100 ° C.
- the diesters are obtained by esterification of the diacids, preferably using a lower aliphatic alcohol (1-4C), in the presence of an acid (preferably sulfuric acid), at the boiling temperature of the reaction medium.
- the amines of formula (III) are marketed or can be obtained in particular by adaptation or application of the methods described in Houben-Weyl "Methoden der Organischen Chemie” Volume XI / 1 pp1-1037 - Georg Thieme Verlag -Stuttgart (1957).
- R T and R 4 are identical and each represent a radical -CO-NR 5 R 6 , -CO-N (CH (CH 2 OH) 2 ) 2 , -CO-N (CH 2 OH) 2 , -CO-N (CH 2 -CH (CH 2 OH) 2) 2 ,
- -CO-N (CH 2 - (CHOH) n -CH 2 OH) 2
- R 2 and R 3 each represent a hydrogen atom, or R represents a CH residue
- Ri and R 3 are identical and each represent a radical -CO-NR 5 R 6 , -CO-N (CH 2 OH) 2 , -CO-N (CH 2 -CH (CH 2 OH) 2 ) 2 , -CO-N (CH 2 - (CHOH) n -CH 2 OH) 2 and R 2 and R 4 each represents a hydrogen atom, or R represents a CH residue
- R 2 and R 3 are identical and each represents a radical -CO-NRsRe, -CO-N (CH (CH 2 OH) 2 ) 2 , -CO-N (CH 2 OH) 2 ,
- Re and Rh are identical and each represents a carboxy radical and Rf and Rg each represent a hydrogen atom, or Re and Rg are identical and each represent a carboxy radical and Rf and Rh each represent a hydrogen atom, either Rf and Rg are identical and each represents a carboxy radical and Re and Rh each represent a hydrogen atom or a reactive derivative of this diacid on an amine HNRcRd (III) in which either Rc represents a hydrogen atom or a radical alkyl and Rd represents a radical -CH 2 - (CHOH) m-CH 2 OH in which m is equal to 0, 1, 2, 3 or 4, -alk-0-alk-CH 2 OH, -alk-O- alk, -CH (CH 2 OH) 2l -C (CH 2 OH) 3 , -C (CH 3 ) (CH 2 OH) 2 -CH 2 -CH (CH 2 OH) 2 or -CH (CH 2 OH) (CHOH) x
- the derivatives of formula (IV) are marketed or can be obtained by application or adaptation of the methods described by H. Meyer, Mont. Chem., 24, 195 (1903) and Mont. Chem., 35, 781 (1914) or by oxidation of the corresponding dimethyl derivatives which are commercially available, for example by means of potassium permanganate at a temperature between 20 ° C and 100 ° C.
- the diesters are obtained by esterification of the diacids, preferably by means of a lower aliphatic alcohol (1-4C), in the presence of acid (preferably sulfuric acid), at the boiling temperature of the reaction medium.
- one of the substituents Ri or Rj represents a radical -CH 2 CI and the other a hydrogen atom on a derivative R 6 OH (VI) for which R 6 has the same meanings as in formula (I) and in which the hydroxy functions are optionally protected in the form of cyclic acetal.
- This reaction is generally carried out by the action of the alkali metal alcoholate (preferably sodium or potassium) corresponding to R 6 OH in an inert solvent such as an ether (tetrahydrofuran, dioxane for example), an amide (dimethylformamide), at a temperature between 0 ° C and the boiling temperature of the reaction mixture.
- the alkali metal alcoholate can be obtained by the action of a base (sodium or potassium hydroxide or methylate) on the corresponding alcohol R 6 OH.
- the derivatives of formula (V) are marketed or can be obtained by the methods described in "The Pyrazines” GB Barlin Chapter 5, pp114- 116 in "The Chemistry of Heterocyclic Compounds” A. Weissberger and EC Taylor Editeurs - 1982 - Interscience Publishers , and in particular by halogenation of the corresponding dimethyl derivative by means of a halogenating agent such as N-chlorosuccinimide in an inert solvent such as carbon tetrachloride, in the presence of an alkyl peroxide (for example benzoyl peroxide) , at a temperature between 40 ° C and the boiling temperature of the reaction medium.
- a halogenating agent such as N-chlorosuccinimide
- an inert solvent such as carbon tetrachloride
- an alkyl peroxide for example benzoyl peroxide
- the R 6 OH (VI) derivatives are marketed or can be obtained in particular by application or adaptation of the methods described in Houben-Weyl "Methoden der Organischen Chemie” Volume VI / 1A part 1, pp1-653 - 4th edition - Georg Thieme Verlag - Stuttgart (1979), volume VI / 1A part 2, pp771-1516 - 4th edition - Georg Thieme Verlag -Stuttgart (1980) and volume VI / 1B pp1-976 - 4th edition - Georg Thieme Verlag - Stuttgart (1984).
- Ri represents a radical -CH 2 -NR 5 R 6 , -CH 2 -N (CH 2 OH) 2 , -CH 2 -N (CH 2 - (CHOH) y -CH 2 OH) 2 , -CH 2 -N (CH (CH 2 OH) 2 ) 2 or
- R 3 or R 4 represents a hydrogen atom and the other is identical to Ri, and R 2 represents an atom of hydrogen, can be prepared by the action of a derivative of formula (V) in which one of the substituents Ri and Rj represents a radical -CH 2 CI and the other a hydrogen atom on an amine HNRcRd (III ) in which Rc and Rd have the same meanings as before.
- This reaction is generally carried out in an inert solvent such as an ether (tetrahydrofuran, dioxane for example) or a chlorinated solvent (carbon tetrachloride, methylene chloride, 1,2-dichloro-2 ethane, chloroform for example) at a temperature comprised between 0 ° C and the boiling temperature of the reaction mixture, optionally in the presence of an acid acceptor such as an organic nitrogenous base (trialkylamine, pyridine, diaza-1, 8-bicyclo [5.4.0] undecene- 7 or diaza-1, 5-bi-cyclo [4.3.0] nonene-5 for example).
- an inert solvent such as an ether (tetrahydrofuran, dioxane for example) or a chlorinated solvent (carbon tetrachloride, methylene chloride, 1,2-dichloro-2 ethane, chloroform for example)
- an acid acceptor such as an organic nitrogenous base (trialkyl
- R 4 and R 4 are identical and each represent a radical -CH 2 -NR 5 R 6 , -CH 2 -N (CH 2 OH) 2 , - CH 2 -N (CH 2 - (CHOH) y -CH 2 OH) 2 , -CH 2 -N (CH (CH 2 OH) 2 ) 2 or -CH 2 -N (CH 2 -CH (CH 2 OH) 2 ) 2 and R 2 and R 3 each represent a hydrogen atom, or R represents a CH residue, Ri and R 3 are identical and each represent a radical -CH 2 -NR 5 R 6 , -CH 2 -N ( CH 2 OH) 2 -CH 2 -N (CH 2 - (CHOH) y -CH 2 OH) 2 , -CH 2 -N (CH (CH 2 OH) 2) 2, or
- R 2 and R 4 each represent a hydrogen atom, or R represents a residue CH
- R 2 and R 3 are identical and each represents a radical -CH 2 -NR 5 R 6 , -CH 2 -N (CH 2 OH) 2 , -CH 2 -N (CH 2 - (CHOH) y -CH 2 OH) 2> -CH 2 -N (CH ( CH 2 OH) 2 ) 2 or
- Ri and R 4 each represent a hydrogen atom can be prepared by the action of a derivative of formula (IV) in which either Re and Rh are identical and each represents a radical -CH 2 CI and Rf and Rg each represent a hydrogen atom, ie Re and Rg are identical and each represent a radical -CH 2 CI and Rf and Rh each represent a hydrogen atom, or Rf and Rg are identical and each represents a radical -CH 2 CI and Re and Rh each represent a hydrogen atom on an amine amine HNRcRd (III) in which Rc and Rd have the same meanings as above.
- formula (IV) in which either Re and Rh are identical and each represents a radical -CH 2 CI and Rf and Rg each represent a hydrogen atom, ie Re and Rg are identical and each represent a radical -CH 2 CI and Rf and Rh each represent a hydrogen atom, or Rf and Rg are identical and each represents a radical -CH 2 CI and Re and Rh each represent
- R 5 has the same meanings as in formula (I) and one of the substituents Rk or RI represents a hydrogen atom and the other a radical NHR 5 in which R 5 has the same meanings as in the formula (I) on an acid HOOC-R 6 (VIII) for which R 6 has the same meanings as in formula (I) or a reactive derivative of this acid and, in particular, a halide of this acid.
- This reaction is generally carried out in the presence of a condensing agent used in peptide chemistry such as a carbodiimide (for example N.N'-dicyclohexylcarbodiimide) or N, N'-diimidazole carbonyl, in an inert solvent such as an ether (tetrahydrofuran, dioxane for example), an amide (dimethylformamide) or a chlorinated solvent (methylene chloride, 1,2-dichloro ethane, chloroform for example) at a temperature between 0 ° C.
- a condensing agent used in peptide chemistry such as a carbodiimide (for example N.N'-dicyclohexylcarbodiimide) or N, N'-diimidazole carbonyl
- an inert solvent such as an ether (tetrahydrofuran, dioxane for example), an amide (dimethylformamide) or a chlorin
- an acid acceptor such as a nitrogenous organic base (trialkylamine, pyridine, diaza-1,8-bicyclo [5.4.0] undecene-7 or diaza-1, 5-bi- cyclo [4.3.0] nonene-5 for example), in a solvent as mentioned above, or a mixture of these solvents, at a temperature between 0 ° C. and the boiling temperature of the reaction mixture.
- an acid chloride (VIII) is used, it is generally carried out within tetrahydrofuran, at a temperature between 0 ° C. and the reflux temperature of the reaction mixture.
- HOOC-R ⁇ (VIII) derivatives are marketed or can be obtained in particular by application or adaptation of the methods described in Houben-Weyl "Methoden der Organischen Chemie” Volume VIII Georg Thieme Verlag -Stuttgart (1952).
- Ri represents a radical -CH 2 -0-R 6 in which R 6 represents a radical -alk-O-alk and one of the substituents R 3 or R 4 represents a hydrogen atom and the other is identical to Ri and R 2 represents a hydrogen atom
- Ri represents a radical -CH 2 -0-R 6 in which R 6 represents a radical -alk-O-alk and one of the substituents R 3 or R 4 represents a hydrogen atom and the other is identical to Ri and R 2 represents a hydrogen atom
- one of the substituents Rm or Rn represents a radical -CH 2 OH and the other a hydrogen atom on a derivative Hal-alk-O-alk (X) for which alk represents an alkyl radical and Hal represents a halogen atom and preferably a chlorine or bromine atom.
- This reaction is generally carried out in an inert solvent such as tetrahydrofuran, at 20 ° C.
- the derivatives of formula (IX) are marketed or can be obtained by the methods described in "The Pyrazines” GB Barlin in “The Chemistry of Heterocyclic Compounds” A. Weissberger and EC Taylor Editeurs - 1982 - Interscience Publishers.
- the Hal-alk-O-alk derivatives are marketed or can be obtained according to the methods described in Houben-Weyl “Methoden der Organischen Chemie” Volume V / 4 Georg Thieme Verlag -Stuttgart (1960).
- R ⁇ and R 4 are identical and each represent a radical -CH 2 -0-R ⁇ in which R ⁇ represents a radical -alk-O-alk and R 2 and R 3 each represents a hydrogen atom, or R represents a CH residue, Ri and R 3 are identical and each represents a radical -CH 2 -0-R ⁇ in which R 6 represents a radical -alk-O-alk and R 2 and R 4 each represent a hydrogen atom, or R represents a CH residue, R 2 and R 3 are identical and each represent a radical -CH 2 -0-R 6 in which R ⁇ represents a radical -alk-O -alk and ⁇ and R 4 each represent a hydrogen atom can be prepared by the action of a derivative of formula (IV) in which either Re and Rh are identical and each represent a radical -CH 2 OH and Rf and Rg represent each a hydrogen atom, ie Re and Rg are identical and each represent a
- reaction mixtures obtained by the various methods described above are treated according to conventional physical (evaporation, extraction, distillation, chromatography, crystallization, for example) or chemical (formation of salts, for example) methods.
- the compounds of formula (I) can optionally be converted into addition salts with a mineral or organic acid by the action of such an acid within an organic solvent such as an alcohol, a ketone, an ether or a solvent chlorine. These salts are also part of the invention.
- salts there may be mentioned the addition salts with mineral or organic acids such as acetate, propionate, succinate, benzoate, fumarate, maleate, oxalate, methanesulfonate, isethionate, theophyllinacetate, salicylate, methylene-bis- ⁇ -oxynaphtoate, hydrochloride, sulfate, nitrate and phosphate.
- mineral or organic acids such as acetate, propionate, succinate, benzoate, fumarate, maleate, oxalate, methanesulfonate, isethionate, theophyllinacetate, salicylate, methylene-bis- ⁇ -oxynaphtoate, hydrochloride, sulfate, nitrate and phosphate.
- 2,5-dimethoxycarbonylpyrazine can be obtained according to W.J. Schut, H.I.X. Mager and W. Berends, Rec. Trav. Chim. Netherlands, 80, 391 (1961).
- Example 5 A solution of 500 mg of 2,5-dimethoxycarbonylpyrazine and 0.48 cm 3 of diethanolamine in 3 cm 3 of ethanol is heated to a temperature close to reflux for 3 hours. The reaction mixture is cooled to 20 ° C. and then the white solid formed is filtered and washed with 2 cm 3 of ethanol.
- a solution of 500 mg of 2,5-dimethoxycarbonylpyrazine and 525 mg of 3-methylamino-1,2-propanediol in 3 cm 3 of ethanol is heated to a temperature close to reflux for 2 hours.
- the reaction mixture is cooled to 20 ° C and then the solution obtained is concentrated under reduced pressure (2.7 kPa) at 40 ° C.
- the residue is taken up in 5 cm 3 of ethanol.
- the suspension is brought to reflux and filtered hot. After the filtrate has cooled, the white solid formed is filtered and then washed with 2 times 10 cm 3 of ethanol.
- Example 10 A solution of 500 mg of 2,6-dimethoxycarbonylpyrazine and 525 mg of 2-amino-2-methyl-1,3-propanediol in 5 cm 3 of ethanol is heated to a temperature close to reflux for 3 hours. The reaction mixture is cooled to a temperature of 20 ° C. then the white solid formed is filtered and washed with 2 times 5 cm 3 of ethanol. 260 mg of N, N'-bis- (1,3-dihydroxy-2-methylprop-2-yl) -pyrazine-2,6-dicarboxamide are thus obtained in the form of a white solid, melting at 169 ° C.
- 2,6-dimethoxycarbonylpyrazine can be obtained as described by H.I.X. Mager and W. Berends, Rec. Trav. Chim. Netherlands, 77.827 (1958).
- the reaction mixture is heated for 5 hours at a temperature close to reflux.
- the reaction mixture is cooled to a temperature of
- the oily residue (11.6 g) is chromatographed on a silica column (0.02-0.045 mm) 4 cm in diameter, eluted with a chloroform-methanol-20% ammonia mixture (24: 6: 1 by volume ) for the first 50 fractions and a 20% chloroform-methanol-ammonia mixture (12: 6: 1 by volume) for the following.
- the fractions containing the product (fractions 50 to 70) are concentrated under reduced pressure (2.7 kPa) at 40 ° C.
- the reaction mixture is heated for 5 hours at a temperature close to reflux.
- the reaction mixture is cooled to 20 ° C and then concentrated under reduced pressure (2.7 kPa) at 40 ° C.
- the residue is dissolved in 100 cm 3 of ethanol and the insoluble material is filtered.
- the solid (1.2 g) is dissolved in
- the pyridine 2,6-dicarboxylic acid dichloride can be obtained according to H. Meyer, Mont. Chem., 24, 195 (1903).
- the solid is filtered and then chromatographed on a silica column (0.02 - 0.045 mm) 3 cm in diameter, eluted with a chloroform-methanol mixture (9: 1 by volume).
- the fractions containing the product are concentrated under reduced pressure (2.7 kPa) at 40 ° C.
- the residue is triturated with 10 cm 3 of a dichloromethane-methanol mixture (19: 1 by volume).
- the solid is filtered and dried at constant weight at 40 C. This gives 90 mg of N, N'-bis- (1,3-dihydroxy-2-methylprop-2-yl) -pyridine-2,6-dicarboxamide under the form of a white solid, melting at 184 ° C.
- the pyridine 3,5-dicarboxylic acid dichloride can be obtained according to H. Meyer and H. Tropsch, Mont. Chem., 35, 781 (1914).
- the oily residue (7.0 g) is chromatographed on a silica column (0.02-0.045 mm), 3.5 cm in diameter, eluted with a 20% chloroform-methanol-ammonia mixture (24: 6: 1 by volume), collecting 100 cm 3 fractions , The fractions containing the product are concentrated under pressure reduced (2.7 kPa) at 40 ° C.
- the orange oil obtained (1.0 g) is taken up in 15 cm 3 of boiling ethanol.
- the mixture is treated with 500 mg of animal black and filtered while hot. The filtrate is left for 2 hours at 20 ° C.
- the solid formed is filtered, rinsed with 2 times 2 cm 3 of ethanol and then dried under reduced pressure (2.7 kPa) at 40 ° C.
- the oily residue is chromatographed on a silica column (0.02-0.045 mm), 3.5 cm in diameter, eluted with a chloroform-methanol-20% ammonia mixture (24: 6: 1 by volume), collecting fractions of 200 cm 3 .
- the fractions containing the product are concentrated under reduced pressure (2.7 kPa) at 40 ° C.
- the brown oil obtained (1.0 g) is taken up in 30 cm 3 of ethanol and 5 cm 3 of a 2N hydrochloric ether solution then 5 cm 3 of diethyl ether.
- the mixture is left for 1 hour at 5 ° C.
- the solid formed is filtered and rinsed with 2 times 10 cm 3 of diethyl ether.
- the solid is recrystallized from 30 cm 3 of ethanol.
- the oily residue (13 g) is chromatographed on a silica column (0.02-0.045 mm), 5 cm in diameter, eluted with a chloroform-methanol-20% ammonia mixture (24: 6: 1 by volume) for the first sixty fractions and a 20% chloroform-methanol-ammonia mixture (12: 6: 1 by volume) for the following, collecting 100 cm 3 fractions.
- the fractions containing the product (fractions 61 to 75) are concentrated under reduced pressure (2.7 kPa) at 40 ° C.
- the orange oil obtained (4.7 g) is chromatographed on a silica column (0.02-0.045 mm), 4 cm in diameter, eluted with a mixture 20% chloroform-methanol-ammonia (12: 6: 1 by volume), collecting 100 cm 3 fractions.
- the fractions containing the product are concentrated under reduced pressure (2.7 kPa) at 40 ° C.
- the residue is triturated successively with 10 cm 3 of acetone and diethyl ether.
- the residual solid is dissolved in 10 cm 3 of ethanol.
- 30 cm 3 of isopropyl ether is added dropwise, then the mixture is left for 48 hours at 20 ° C.
- the orange solid formed is filtered, rinsed with 3 times 5 cm 3 of a methanol-isopropyl ether mixture (1: 9 by volume) and then dried under reduced pressure (2.7 kPa) at 40 ° C. 260 mg of N, N'-bis- (1,3-dihydroxyprop-2-yl) -pyrazine-2,5-dimethanamine are thus obtained in the form of an orange solid, melting at 87 ° C.
- the colorless oil obtained (0.7 g) is triturated successively with 10 cm 3 of acetone and diethyl ether.
- the residual solid is dissolved in 50 cm 3 of ethanol.
- 30 cm 3 of isopropyl ether is added dropwise, then the mixture is left for 48 hours at 20 ° C.
- the white solid formed is filtered, rinsed with 5 times 5 cm 3 of diethyl ether and then dried under reduced pressure (2.7 kPa) at 40 ° C.
- 440 mg of N, N ′ - (1, 3-dihydroxy-2-methylprop-2-yl) -pyridine-2,6-dimethanamine are thus obtained in the form of a white solid, melting at 97 ° C.
- 2,6-bis- (2 ', 2'-dimethyl-1', 3'-dioxoian-4'-ylméthyloxyméthyl) pyridine can be prepared as follows: to a solution of 3.30 g of (S) (+) - 2,2- dimethyl-1,3-dioxolane-4-methanol in 125 cm 3 of o-xylene 4.95 g of potassium hydroxide are added and then the reaction mixture is heated for 4 hours to 130 ° C. The reaction mixture is cooled to 20 ° C. and then 2.20 g of 2,6-bis (chloromethyl) pyridine are added. The reaction medium is heated for 3 hours at 130 ° C.
- 2,6-bis- (chloromethyl) -pyridine can be pre-prepared according to W. Baker, J. Chem. Soc, 3594 (1958).
- the solid formed is filtered and then rinsed with 30 cm 3 in total of isopropyl ether and then dried to constant weight to give 0.35 g of 2,5-bis-N, N '- (3-methoxyprop-1- ylamido) pyridine in the form of a beige solid, melting at 124 ° C.
- Example 24 To a solution of 7.1 g of 2,6-pyridinedimethanol in 100 cm 3 of tetrahydrofuran is added successively 6.91 g of potassium carbonate and 8.75 g of tetrabutyl ammonium hydrogen sulphate. The reaction mixture is cooled in an ice bath to 20 ° C and then 6.60 g of potassium hydroxide are added while maintaining the temperature of the reaction mixture at 30 ° C. After 15 minutes of stirring at this temperature, a solution of 4.73 cm 3 of 2-bromoethyl methyl ether in 10 cm 3 of tetrahydrofuran is added in approximately 15 minutes. The reaction mixture is stirred for 12 hours at 20 ° C.
- the residual oil (10 g) is purified by chromatography on a silica column (0.020-0.045 mm), eluting with a chloroform-methanol-20% ammonia mixture (24: 6: 1 by volume) for the first 13 fractions and 20% chloroform-methanol-ammonia (12: 6: 2 by volume) for the following, collecting fractions of 100 cm 3 .
- the fractions containing the expected product are combined and concentrated under reduced pressure (2.7 kPa) at 50 ° C.
- the yellow oil obtained (1.3 g) is again purified by chromatography on a silica column (0.020-0.045 mm), eluting with a chloroform-methanol-20% ammonia mixture (24: 6: 1 by volume) , by collecting fractions of 100 cm 3 .
- the fractions containing the expected product are combined and concentrated under reduced pressure (2.7 kPa) at 50 ° C.
- the yellow oil obtained (0.6 g) is crystallized from a methanol-methyl ethyl ketone-acetone mixture.
- the 2,2-bis (acetoxymethyl) propionic acid chloride can be prepared according to the method described by I. Henrik, J. Amer. Chem. Soc. 118, 6388-95 (1996).
- the compounds of formula (I) have interesting pharmacological properties. They are hypoglycemic agents.
- hypoglycaemic activity of the compounds of formula (I) was determined on the hyperglycemic response to the administration of glucose by the oral route in normoglycemic mice, according to the following protocol:
- mice weighing between 22 and 26 g are left on an empty stomach for 2 hours. At the end of this period, blood sugar is measured and, immediately after, a dose of glucose (2 g / kg) is administered orally. Thirty minutes later, the blood sugar is measured again.
- the mice which respond with a hyperglycaemia greater than 170 mg / dl are selected and used to detect the hypoglycaemic activity of the compounds according to the invention.
- mice thus chosen are divided into groups of at least 10 animals. Separate groups receive a solution of 3 to 50 mg / kg of the test product in a vehicle such as water or a mixture of methylcellulose / tween and water or from the vehicle once a day by gastric tubing.
- the treatment lasts 4 days. ⁇ m ⁇ to 4 days after the last treatment, the animals receive a dose of glucose (2 g / kg) and the glycaemia is measured 20 to 40 minutes later.
- the percentage inhibition of the hyperglycemic response to glucose administration is calculated relative to the response measured in the group treated by the vehicle.
- the compounds according to the invention have a percentage inhibition of blood sugar greater than or equal to 10%.
- the compounds of general formula (I) according to the invention have low toxicity.
- Their LD50 is greater than 2000 mg / kg orally in mice.
- these products are useful in the prevention and treatment of diabetes, and in particular of type II diabetes (diabetes PID), obese diabetes, fiftieth diabetes, metaplethoric diabetes, diabetes in the elderly. and mild diabetes. They can be used in addition to insulin therapy in insulin-dependent diabetes, where they make it possible to gradually decrease the dose of insulin, unstable diabetes, insulin-resistant diabetes, in addition to sulphonylureas when these do not determine sufficient drop of glycemia. These products can also be used in the complications of diabetes such as hyperlipemias, lipid metabolism disorders, dyslipemias, obesity.
- Atherosclerotic lesions are also useful in the prevention and treatment of atherosclerotic lesions and their complications (coronopathies, myocardial infarction, cardiomyopathies, evolution of these three complications towards left ventricular insufficiency, various arteriopathies, arteritis of the lower limbs with lameness and evolution towards ulcers and gangrene, cerebrovascular insufficiency and its complications, sexual impotence of vascular origin), diabetic retinopathy and all its manifestations (increase in capillary permeability, dilation and capillary thrombosis, microaneurysms, arteriovenous shunt, venous dilation, punctual and macular hemorrhages, exudates, macular edemas, manifestations of proliferative retinopathy: neovessels, proliferative retinitis scars, vitreous hemorrhages, retinal detachment), diabetic cataracts, diabetic neuropathy in its
- the medicaments according to the invention consist of a compound according to the invention or a combination of these products, in the pure state or in the form of a composition in which it is associated with any other pharmaceutically compatible product, which may be inert or physiologically active.
- the medicaments according to the invention can be used orally, parenterally, rectally or topically.
- compositions for oral administration tablets, pills, powders (gelatin capsules, cachets) or granules can be used.
- the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon.
- inert diluents such as starch, cellulose, sucrose, lactose or silica
- These compositions can also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (dragees) or a varnish.
- compositions for oral administration there may be used pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or oil paraffin.
- inert diluents such as water, ethanol, glycerol, vegetable oils or oil paraffin.
- These compositions can include substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
- the sterile compositions for parenteral administration can preferably be aqueous or non-aqueous solutions, suspensions or emulsions.
- solvent or vehicle water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or the like, can be used. suitable organic solvents.
- These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be do this in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
- compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols.
- compositions for topical administration can be, for example, creams, lotions, eye drops, mouthwashes, nasal drops or aerosols.
- the doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally between 150 mg and 600 mg per day orally for an adult with unit doses ranging from 50 mg to 200 mg of active substance.
- the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated.
- capsules containing 50 mg of active product having the following composition are prepared:
- Tablets containing 50 mg of active product having the following composition are prepared according to the usual technique:
- a solution for injection containing 50 mg of active product having the following composition is prepared:
- the invention also relates to the use of the compounds of general formula (I) for the preparation of pharmaceutical compositions useful for the treatment or prevention of diabetes and the complications of diabetes.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9810880-8A BR9810880A (pt) | 1997-07-17 | 1998-07-15 | Medicamentos, compostos derivados de pirazina, processo para preparação dos compostos, e, utilização de um composto |
JP2000503069A JP4443036B2 (ja) | 1997-07-17 | 1998-07-15 | ピラジン誘導体、それらの製造及びそれらを含有する薬剤 |
MXPA00000280A MXPA00000280A (es) | 1997-07-17 | 1998-07-15 | Derivados de pirazina, su preparacion y los medicamentos que los contienen. |
DE69818679T DE69818679T2 (de) | 1997-07-17 | 1998-07-15 | Pyrazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
NZ501906A NZ501906A (en) | 1997-07-17 | 1998-07-15 | Pyrazine and pyridine derivatives for treating diabetes |
DK98939676T DK1001944T3 (da) | 1997-07-17 | 1998-07-15 | Pyrazinderivater, deres fremstilling samt medikamenter indeholdende disse forbindelser |
AU88102/98A AU747127B2 (en) | 1997-07-17 | 1998-07-15 | Pyrazine derivatives, preparation and medicines containing them |
IL13404098A IL134040A0 (en) | 1997-07-17 | 1998-07-15 | Pyrazine derivatives, their preparation and medicines containing them |
EP98939676A EP1001944B1 (fr) | 1997-07-17 | 1998-07-15 | Derives de pyrazine, leur preparation et les medicaments les contenant |
SK48-2000A SK482000A3 (en) | 1997-07-17 | 1998-07-15 | Pyrazine derivatives, preparation and medicines containing them |
HU0004602A HUP0004602A3 (en) | 1997-07-17 | 1998-07-15 | Pyrazine and pyridine derivatives, preparation and medicines containing them |
AT98939676T ATE251144T1 (de) | 1997-07-17 | 1998-07-15 | Pyrazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
PL98338148A PL338148A1 (en) | 1997-07-17 | 1998-07-15 | Derivatives of pyrazine, method of obtaining and drugs containing them |
KR1020007000465A KR20010021901A (ko) | 1997-07-17 | 1998-07-15 | 피라진 유도체, 제조방법 및 이를 함유하는 약제 |
CA002296727A CA2296727C (fr) | 1997-07-17 | 1998-07-15 | Derives de pyrazine, leur preparation et les medicaments les contenant |
NO20000198A NO20000198D0 (no) | 1997-07-17 | 2000-01-14 | Pyrazinderivater, deres fremstilling samt medikamenter inneholdende forbindelsene |
US09/483,984 US6399613B1 (en) | 1997-07-17 | 2000-01-14 | Pyrazine derivatives, their preparation and medicaments containing them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR97/09058 | 1997-07-17 | ||
FR9709058A FR2766187B1 (fr) | 1997-07-17 | 1997-07-17 | Derives de pyrazine, leur preparation et les medicaments les contenant |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/483,984 Continuation US6399613B1 (en) | 1997-07-17 | 2000-01-14 | Pyrazine derivatives, their preparation and medicaments containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999003844A1 true WO1999003844A1 (fr) | 1999-01-28 |
Family
ID=9509300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/001542 WO1999003844A1 (fr) | 1997-07-17 | 1998-07-15 | Derives de pyrazine, leur preparation et les medicaments les contenant |
Country Status (24)
Country | Link |
---|---|
US (1) | US6399613B1 (fr) |
EP (1) | EP1001944B1 (fr) |
JP (1) | JP4443036B2 (fr) |
KR (1) | KR20010021901A (fr) |
CN (1) | CN1264371A (fr) |
AT (1) | ATE251144T1 (fr) |
AU (1) | AU747127B2 (fr) |
BR (1) | BR9810880A (fr) |
CA (1) | CA2296727C (fr) |
DE (1) | DE69818679T2 (fr) |
DK (1) | DK1001944T3 (fr) |
ES (1) | ES2205536T3 (fr) |
FR (1) | FR2766187B1 (fr) |
HU (1) | HUP0004602A3 (fr) |
IL (1) | IL134040A0 (fr) |
MX (1) | MXPA00000280A (fr) |
NO (1) | NO20000198D0 (fr) |
NZ (1) | NZ501906A (fr) |
PL (1) | PL338148A1 (fr) |
PT (1) | PT1001944E (fr) |
RU (1) | RU2194703C2 (fr) |
SK (1) | SK482000A3 (fr) |
WO (1) | WO1999003844A1 (fr) |
ZA (1) | ZA986337B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1159255A2 (fr) * | 1999-03-12 | 2001-12-05 | Isis Innovation Limited | Amine bis (1, 3-dihydroxy-prop-2-yl) et derives intervenant dans la fabrication de polymeres |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7598278B2 (en) * | 2002-04-11 | 2009-10-06 | L'oreal | Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss |
JP2008543953A (ja) * | 2006-04-20 | 2008-12-04 | テバ ファーマシューティカル インダストリーズ リミティド | エスゾピクロン結晶形態a、実質的に純粋なエスゾピクロン及び光学的に豊富なエスゾピクロンを調製するための方法 |
US20080015197A1 (en) * | 2006-06-26 | 2008-01-17 | Alex Mainfeld | Process for the preparatrion of zopiclone |
EP2032557A2 (fr) * | 2007-01-31 | 2009-03-11 | Teva Pharmaceutical Industries Ltd. | Procédés de préparation d'eszopiclone |
CN101891679B (zh) * | 2009-05-19 | 2014-04-16 | 上海华明高技术(集团)有限公司 | 吡啶二甲酸与二氨基吡啶质子转移化合物的制备方法 |
FR3030248B1 (fr) | 2014-12-22 | 2018-03-23 | L'oreal | Association derive d'acide pyridine-dicarboxylique/agent anti-oxydant particulier |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0010896A1 (fr) * | 1978-10-18 | 1980-05-14 | Pfizer Inc. | Composés organiques diaminés utilisables comme substances actives hypoglycémiques administrables par voie orale et compositions pharmaceutiques les contenant |
DE3703959A1 (de) * | 1987-02-10 | 1988-08-18 | Hoechst Ag | Pyridin-2,4- und 2,5-dicarbonsaeureamide, verfahren zu ihrer herstellung, verwendung derselben sowie arzneimittel auf basis dieser verbindungen |
JPH01117863A (ja) * | 1987-10-30 | 1989-05-10 | Toyobo Co Ltd | 新規なアミド化合物 |
EP0463592A1 (fr) * | 1990-06-28 | 1992-01-02 | Hoechst Aktiengesellschaft | N-oxyde-pyridines 2,4- et 2,5-substituées, procédés pour leurs préparation et leur utilisation |
-
1997
- 1997-07-17 FR FR9709058A patent/FR2766187B1/fr not_active Expired - Fee Related
-
1998
- 1998-07-15 BR BR9810880-8A patent/BR9810880A/pt not_active IP Right Cessation
- 1998-07-15 IL IL13404098A patent/IL134040A0/xx unknown
- 1998-07-15 HU HU0004602A patent/HUP0004602A3/hu unknown
- 1998-07-15 CA CA002296727A patent/CA2296727C/fr not_active Expired - Fee Related
- 1998-07-15 KR KR1020007000465A patent/KR20010021901A/ko not_active Application Discontinuation
- 1998-07-15 RU RU2000103449/04A patent/RU2194703C2/ru not_active IP Right Cessation
- 1998-07-15 PL PL98338148A patent/PL338148A1/xx unknown
- 1998-07-15 NZ NZ501906A patent/NZ501906A/en unknown
- 1998-07-15 EP EP98939676A patent/EP1001944B1/fr not_active Expired - Lifetime
- 1998-07-15 DE DE69818679T patent/DE69818679T2/de not_active Expired - Lifetime
- 1998-07-15 AU AU88102/98A patent/AU747127B2/en not_active Ceased
- 1998-07-15 CN CN98807199A patent/CN1264371A/zh active Pending
- 1998-07-15 JP JP2000503069A patent/JP4443036B2/ja not_active Expired - Fee Related
- 1998-07-15 AT AT98939676T patent/ATE251144T1/de not_active IP Right Cessation
- 1998-07-15 PT PT98939676T patent/PT1001944E/pt unknown
- 1998-07-15 ES ES98939676T patent/ES2205536T3/es not_active Expired - Lifetime
- 1998-07-15 SK SK48-2000A patent/SK482000A3/sk unknown
- 1998-07-15 MX MXPA00000280A patent/MXPA00000280A/es unknown
- 1998-07-15 DK DK98939676T patent/DK1001944T3/da active
- 1998-07-15 WO PCT/FR1998/001542 patent/WO1999003844A1/fr not_active Application Discontinuation
- 1998-07-16 ZA ZA986337A patent/ZA986337B/xx unknown
-
2000
- 2000-01-14 US US09/483,984 patent/US6399613B1/en not_active Expired - Fee Related
- 2000-01-14 NO NO20000198A patent/NO20000198D0/no not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0010896A1 (fr) * | 1978-10-18 | 1980-05-14 | Pfizer Inc. | Composés organiques diaminés utilisables comme substances actives hypoglycémiques administrables par voie orale et compositions pharmaceutiques les contenant |
DE3703959A1 (de) * | 1987-02-10 | 1988-08-18 | Hoechst Ag | Pyridin-2,4- und 2,5-dicarbonsaeureamide, verfahren zu ihrer herstellung, verwendung derselben sowie arzneimittel auf basis dieser verbindungen |
JPH01117863A (ja) * | 1987-10-30 | 1989-05-10 | Toyobo Co Ltd | 新規なアミド化合物 |
EP0463592A1 (fr) * | 1990-06-28 | 1992-01-02 | Hoechst Aktiengesellschaft | N-oxyde-pyridines 2,4- et 2,5-substituées, procédés pour leurs préparation et leur utilisation |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, vol. 111, no. 21, 20 November 1989, Columbus, Ohio, US; abstract no. 194802s, TAGUCHI, HIROAKI ET AL: "Preparation of heterocyclic diamides as allergy inhibitors" page 779; XP002078186 * |
KUMAR S ET AL: "Synthetic Ionophores Part 14: Effect of Pyridine and Thioether Ligating Units on AgSelectivity in 18-Membered Diamide-Diester Macrocycles<1", TETRAHEDRON., vol. 52, no. 42, 14 October 1996 (1996-10-14), OXFORD GB, pages 13483-13492, XP004105323 * |
P.D.J. GROOTENHUIS ET AL.: "Complexes of macromolecular polyethers and neutral guest molecules: a systematic approach to the complexation of water molecules by 2,6-pyridinium crown ethers", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 108, no. 4, 1986, Washington DC US, pages 780 - 788, XP002078185 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1159255A2 (fr) * | 1999-03-12 | 2001-12-05 | Isis Innovation Limited | Amine bis (1, 3-dihydroxy-prop-2-yl) et derives intervenant dans la fabrication de polymeres |
Also Published As
Publication number | Publication date |
---|---|
NO20000198L (no) | 2000-01-14 |
PT1001944E (pt) | 2004-02-27 |
US6399613B1 (en) | 2002-06-04 |
EP1001944B1 (fr) | 2003-10-01 |
ATE251144T1 (de) | 2003-10-15 |
KR20010021901A (ko) | 2001-03-15 |
NZ501906A (en) | 2002-04-26 |
EP1001944A1 (fr) | 2000-05-24 |
MXPA00000280A (es) | 2002-04-17 |
FR2766187B1 (fr) | 2000-06-02 |
DK1001944T3 (da) | 2004-02-09 |
JP4443036B2 (ja) | 2010-03-31 |
CA2296727A1 (fr) | 1999-01-28 |
DE69818679T2 (de) | 2004-07-29 |
ES2205536T3 (es) | 2004-05-01 |
HUP0004602A3 (en) | 2001-12-28 |
AU747127B2 (en) | 2002-05-09 |
CA2296727C (fr) | 2009-06-09 |
IL134040A0 (en) | 2001-04-30 |
NO20000198D0 (no) | 2000-01-14 |
CN1264371A (zh) | 2000-08-23 |
ZA986337B (en) | 1999-01-27 |
BR9810880A (pt) | 2002-05-21 |
HUP0004602A2 (hu) | 2001-11-28 |
FR2766187A1 (fr) | 1999-01-22 |
RU2194703C2 (ru) | 2002-12-20 |
JP2001510188A (ja) | 2001-07-31 |
AU8810298A (en) | 1999-02-10 |
PL338148A1 (en) | 2000-09-25 |
DE69818679D1 (de) | 2003-11-06 |
SK482000A3 (en) | 2000-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0092458A2 (fr) | Dérives d'imidazo(1,2-a)pyridine, leur préparation et leur application en thérapeutique | |
CH646687A5 (fr) | Derives de l'acide cyclohexane carboxylique. | |
EP1001944B1 (fr) | Derives de pyrazine, leur preparation et les medicaments les contenant | |
FR2659653A1 (fr) | Derives de l'uree, leur preparation et les medicaments les contenant. | |
EP1001942B1 (fr) | Polyhydroxybutylpyrazines, leur preparation et medicaments les contenant | |
BE1003519A3 (fr) | Nouveaux derives de la carbonyl-2 n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. | |
EP1001943B1 (fr) | Derives de polyhydroxyalkylpyrazines, leur preparation et medicaments les contenant | |
EP0998465B1 (fr) | Derives de polyhydroxylalkylpyrazine, leur preparation, medicaments les contenant | |
EP0233801B1 (fr) | Nouveaux amides substitués, leur préparation et les compositions pharmaceutiques qui les contiennent | |
BE1003518A3 (fr) | Nouveaux derives de la methoxycarbonyl-2-n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. | |
CH648483A5 (fr) | Composition pharmaceutique contre l'arthrite rhumatoide. | |
EP0323303B1 (fr) | Dérivés de nicotinoyl-pipérazine, procédé de préparation et utilisation en thérapeutique | |
CA2337350C (fr) | Derives de polyhydroxyalkylpyrazine, leur preparation et compositions pharmaceutiques les contenant | |
CZ2000120A3 (cs) | Deriváty pyrazinu, způsob jejich přípravy a léčiva, která je obsahuj | |
FR2528834A1 (fr) | Sels d'ammonium quaternaires d'amines cycliques disubstituees en a et a' par des groupes phenylcarbamoyle eventuellement substitues sur le phenyl, et medicaments a action antiarythmique comportant lesdits sels | |
WO1999003840A1 (fr) | Medicaments contenant des derives de polyhydroxyalkylpyrazine, les nouveaux derives de polyhydroxyalkylpyrazine et leur preparation | |
FR2766180A1 (fr) | Medicaments contenant en tant que principe actif un derive de 2-(1,2,3,4-tetrahydroxybutyl)pyrazine,nouveaux derives de 2-(1,2,3,4-tetrahydroxybutyl) pyrazine et leur preparation | |
FR2592880A2 (fr) | Nouveaux amides substitues, leur preparation et les medicaments qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 134040 Country of ref document: IL Ref document number: 98807199.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 88102/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 501906 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/000280 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2296727 Country of ref document: CA Ref document number: 2296727 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-120 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09483984 Country of ref document: US Ref document number: 1020007000465 Country of ref document: KR Ref document number: 482000 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998939676 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-120 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1998939676 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007000465 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 88102/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998939676 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-120 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007000465 Country of ref document: KR |